Coherus Oncology initiated with an Outperform at Oppenheimer ahead of readouts

  Oppenheimer analyst Jay Olson initiated coverage of Coherus Oncology (CHRS) with an Outperform rating and $10 price target citing upcoming clinical readouts in 2026 across multiple cancers for lead anti-CCR8 antibody tagmokitug combined with in-licensed, commercial PD-1 backbone Loqtorzi. Additionally, the firm thinks casdozokitug, Coherus’ “only-in-class” anti-IL-27 antibody, represents “a high-potential early-stage opportunity,” the analyst tells investors.

https://www.tipranks.com/news/the-fly/coherus-oncology-initiated-with-an-outperform-at-oppenheimer-ahead-of-readouts-thefly